ALK-positive NSCLC: updates on crizotinib and alectinib

PROFILE 1014 was the first study to define the role of the ALK inhibitor crizotinib in the first-line treatment of patients with ALK-positive lung cancer. It compared crizotinib 250 mg twice daily (n = 172) with pemetrexed plus cisplatin (n = 171) in patients with ALK-positive, locally advanced, recurrent or metastatic non-squamous NSCLC in the first-line setting. Read more ...